A New Generation of Drug Therapies Requires New Business Strategies

Insight Exchange by L.E.K. Consulting

Today we look at how advanced therapeutic modalities (ATMs) are revolutionizing drug discovery, development and manufacturing, presenting both unparalleled opportunities and new challenges for businesses.

Drawing from their knowledge, our experts Alex Vadas, Adam Siebert and Jeff Holder unpack how new drug therapies such as engineered cell therapies, gene therapies and nucleic acid therapies are revolutionizing patient care and treatment options. They highlight the need for innovative business strategies to navigate complex manufacturing processes and supply chain logistics, the role of regulatory engagement, and the influence of artificial intelligence (AI) and machine learning in the realm of drug discovery.

Key points/topics covered:

• The transformative impact of new drug therapies on life sciences, requiring adaptations in business strategies
• The complexity of manufacturing for ATMs and its effect on the commercial viability of new treatments
• The importance of regulatory engagement in streamlining the drug development timeline for advanced therapies
• The intersection of AI and machine learning in expediting drug discovery for cell and gene therapies
• Manufacturing efficiency and supply chain consistency as a key differentiator in the outcomes and success rates of ATMs
  Interested in learning more? Read our Harvard Business Review article, A New Generation of Drug Therapies Requires New Business Strategies.

Connect with our experts on LinkedIn:
Alex Vadas, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/alexvadas/
Adam Siebert, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/adam-siebert-8772b327/
Jeff Holder, Managing Director, L.E.K. Consulting: https://www.linkedin.com/in/jeff-holder-ph-d-7a391087/

Visit L.E.K. Consulting at https://www.lek.com/